Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome
Intellectual disability is the most limiting hallmark of Down syndrome, for which there is no gold-standard clinical treatment yet. The endocannabinoid system is a widespread neuromodulatory system involved in multiple functions including learning and memory processes. Alterations of this system con...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-05-01
|
| Series: | Neurobiology of Disease |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0969996118306855 |
| _version_ | 1818574450678824960 |
|---|---|
| author | Alba Navarro-Romero Anna Vázquez-Oliver Maria Gomis-González Carlos Garzón-Montesinos Rafael Falcón-Moya Antoni Pastor Elena Martín-García Nieves Pizarro Arnau Busquets-Garcia Jean-Michel Revest Pier-Vincenzo Piazza Fátima Bosch Mara Dierssen Rafael de la Torre Antonio Rodríguez-Moreno Rafael Maldonado Andrés Ozaita |
| author_facet | Alba Navarro-Romero Anna Vázquez-Oliver Maria Gomis-González Carlos Garzón-Montesinos Rafael Falcón-Moya Antoni Pastor Elena Martín-García Nieves Pizarro Arnau Busquets-Garcia Jean-Michel Revest Pier-Vincenzo Piazza Fátima Bosch Mara Dierssen Rafael de la Torre Antonio Rodríguez-Moreno Rafael Maldonado Andrés Ozaita |
| author_sort | Alba Navarro-Romero |
| collection | DOAJ |
| description | Intellectual disability is the most limiting hallmark of Down syndrome, for which there is no gold-standard clinical treatment yet. The endocannabinoid system is a widespread neuromodulatory system involved in multiple functions including learning and memory processes. Alterations of this system contribute to the pathogenesis of several neurological and neurodevelopmental disorders. However, the involvement of the endocannabinoid system in the pathogenesis of Down syndrome has not been explored before. We used the best-characterized preclinical model of Down syndrome, the segmentally trisomic Ts65Dn model. In male Ts65Dn mice, cannabinoid type-1 receptor (CB1R) expression was enhanced and its function increased in hippocampal excitatory terminals. Knockdown of CB1R in the hippocampus of male Ts65Dn mice restored hippocampal-dependent memory. Concomitant with this result, pharmacological inhibition of CB1R restored memory deficits, hippocampal synaptic plasticity and adult neurogenesis in the subgranular zone of the dentate gyrus. Notably, the blockade of CB1R also normalized hippocampal-dependent memory in female Ts65Dn mice. To further investigate the mechanisms involved, we used a second transgenic mouse model overexpressing a single gene candidate for Down syndrome cognitive phenotypes, the dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). CB1R pharmacological blockade similarly improved cognitive performance, synaptic plasticity and neurogenesis in transgenic male Dyrk1A mice. Our results identify CB1R as a novel druggable target potentially relevant for the improvement of cognitive deficits associated with Down syndrome. |
| first_indexed | 2024-12-15T00:26:49Z |
| format | Article |
| id | doaj.art-5590c1019a6448d3ada0ed930e82b310 |
| institution | Directory Open Access Journal |
| issn | 1095-953X |
| language | English |
| last_indexed | 2024-12-15T00:26:49Z |
| publishDate | 2019-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Neurobiology of Disease |
| spelling | doaj.art-5590c1019a6448d3ada0ed930e82b3102022-12-21T22:42:09ZengElsevierNeurobiology of Disease1095-953X2019-05-0112592106Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndromeAlba Navarro-Romero0Anna Vázquez-Oliver1Maria Gomis-González2Carlos Garzón-Montesinos3Rafael Falcón-Moya4Antoni Pastor5Elena Martín-García6Nieves Pizarro7Arnau Busquets-Garcia8Jean-Michel Revest9Pier-Vincenzo Piazza10Fátima Bosch11Mara Dierssen12Rafael de la Torre13Antonio Rodríguez-Moreno14Rafael Maldonado15Andrés Ozaita16Laboratory of Neuropharmacology-NeuroPhar, Department of Experimental and Health Sciences, University Pompeu Fabra, 08003 Barcelona, SpainLaboratory of Neuropharmacology-NeuroPhar, Department of Experimental and Health Sciences, University Pompeu Fabra, 08003 Barcelona, SpainLaboratory of Neuropharmacology-NeuroPhar, Department of Experimental and Health Sciences, University Pompeu Fabra, 08003 Barcelona, SpainLaboratory of Cellular Neuroscience and Plasticity, Department of Physiology, Anatomy and Cell Biology, University Pablo de Olavide, Ctra Utrera km. 1, 41013 Seville, SpainLaboratory of Cellular Neuroscience and Plasticity, Department of Physiology, Anatomy and Cell Biology, University Pablo de Olavide, Ctra Utrera km. 1, 41013 Seville, SpainIntegrative Pharmacology and Systems Neuroscience Research Group, Hospital del Mar Medical Research Institute, 08003 Barcelona, Spain; CIBER Pathophysiology of Obesity and Nutrition, Institute of Health Carlos III, 28029 Madrid, SpainLaboratory of Neuropharmacology-NeuroPhar, Department of Experimental and Health Sciences, University Pompeu Fabra, 08003 Barcelona, Spain; Department of Psychobiology and Methodology of Health Sciences, Universitat Autònoma de Barcelona, SpainIntegrative Pharmacology and Systems Neuroscience Research Group, Hospital del Mar Medical Research Institute, 08003 Barcelona, SpainLaboratory of Neuropharmacology-NeuroPhar, Department of Experimental and Health Sciences, University Pompeu Fabra, 08003 Barcelona, SpainINSERM U1215, Neurocentre Magendie, Physiopathology and Therapeutic Approaches of Stress-Related Diseases, 33077 Bordeaux, FranceINSERM U1215, Neurocentre Magendie, Physiopathology and Therapeutic Approaches of Stress-Related Diseases, 33077 Bordeaux, FranceCenter of Animal Biotechnology and Gene Therapy (CBATEG), Spain; Department of Biochemistry and Molecular Biology, School of Veterinary Medicine, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain; CIBER Diabetes and Associated Metabolic Disorders (CIBERDEM), 08017 Madrid, SpainCellular & Systems Neurobiology, Systems Biology Program, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, 08003 Barcelona, Spain; CIBER Rare Disorders (CIBERER), Spain; Hospital del Mar Medical Research Institute, 08003 Barcelona, SpainIntegrative Pharmacology and Systems Neuroscience Research Group, Hospital del Mar Medical Research Institute, 08003 Barcelona, Spain; CIBER Pathophysiology of Obesity and Nutrition, Institute of Health Carlos III, 28029 Madrid, SpainLaboratory of Cellular Neuroscience and Plasticity, Department of Physiology, Anatomy and Cell Biology, University Pablo de Olavide, Ctra Utrera km. 1, 41013 Seville, SpainLaboratory of Neuropharmacology-NeuroPhar, Department of Experimental and Health Sciences, University Pompeu Fabra, 08003 Barcelona, SpainLaboratory of Neuropharmacology-NeuroPhar, Department of Experimental and Health Sciences, University Pompeu Fabra, 08003 Barcelona, Spain; Corresponding author at: Laboratory of Neuropharmacology-NeuroPhar, Department of Experimental and Health Sciences, Univ. Pompeu Fabra, C/Dr Aiguader 88, 08003 Barcelona, Spain.Intellectual disability is the most limiting hallmark of Down syndrome, for which there is no gold-standard clinical treatment yet. The endocannabinoid system is a widespread neuromodulatory system involved in multiple functions including learning and memory processes. Alterations of this system contribute to the pathogenesis of several neurological and neurodevelopmental disorders. However, the involvement of the endocannabinoid system in the pathogenesis of Down syndrome has not been explored before. We used the best-characterized preclinical model of Down syndrome, the segmentally trisomic Ts65Dn model. In male Ts65Dn mice, cannabinoid type-1 receptor (CB1R) expression was enhanced and its function increased in hippocampal excitatory terminals. Knockdown of CB1R in the hippocampus of male Ts65Dn mice restored hippocampal-dependent memory. Concomitant with this result, pharmacological inhibition of CB1R restored memory deficits, hippocampal synaptic plasticity and adult neurogenesis in the subgranular zone of the dentate gyrus. Notably, the blockade of CB1R also normalized hippocampal-dependent memory in female Ts65Dn mice. To further investigate the mechanisms involved, we used a second transgenic mouse model overexpressing a single gene candidate for Down syndrome cognitive phenotypes, the dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). CB1R pharmacological blockade similarly improved cognitive performance, synaptic plasticity and neurogenesis in transgenic male Dyrk1A mice. Our results identify CB1R as a novel druggable target potentially relevant for the improvement of cognitive deficits associated with Down syndrome.http://www.sciencedirect.com/science/article/pii/S0969996118306855Down syndromeIntellectual disabilityCognitive deficitsCannabinoid receptor type-1Endocannabinoid systemHippocampus |
| spellingShingle | Alba Navarro-Romero Anna Vázquez-Oliver Maria Gomis-González Carlos Garzón-Montesinos Rafael Falcón-Moya Antoni Pastor Elena Martín-García Nieves Pizarro Arnau Busquets-Garcia Jean-Michel Revest Pier-Vincenzo Piazza Fátima Bosch Mara Dierssen Rafael de la Torre Antonio Rodríguez-Moreno Rafael Maldonado Andrés Ozaita Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome Neurobiology of Disease Down syndrome Intellectual disability Cognitive deficits Cannabinoid receptor type-1 Endocannabinoid system Hippocampus |
| title | Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome |
| title_full | Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome |
| title_fullStr | Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome |
| title_full_unstemmed | Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome |
| title_short | Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome |
| title_sort | cannabinoid type 1 receptor blockade restores neurological phenotypes in two models for down syndrome |
| topic | Down syndrome Intellectual disability Cognitive deficits Cannabinoid receptor type-1 Endocannabinoid system Hippocampus |
| url | http://www.sciencedirect.com/science/article/pii/S0969996118306855 |
| work_keys_str_mv | AT albanavarroromero cannabinoidtype1receptorblockaderestoresneurologicalphenotypesintwomodelsfordownsyndrome AT annavazquezoliver cannabinoidtype1receptorblockaderestoresneurologicalphenotypesintwomodelsfordownsyndrome AT mariagomisgonzalez cannabinoidtype1receptorblockaderestoresneurologicalphenotypesintwomodelsfordownsyndrome AT carlosgarzonmontesinos cannabinoidtype1receptorblockaderestoresneurologicalphenotypesintwomodelsfordownsyndrome AT rafaelfalconmoya cannabinoidtype1receptorblockaderestoresneurologicalphenotypesintwomodelsfordownsyndrome AT antonipastor cannabinoidtype1receptorblockaderestoresneurologicalphenotypesintwomodelsfordownsyndrome AT elenamartingarcia cannabinoidtype1receptorblockaderestoresneurologicalphenotypesintwomodelsfordownsyndrome AT nievespizarro cannabinoidtype1receptorblockaderestoresneurologicalphenotypesintwomodelsfordownsyndrome AT arnaubusquetsgarcia cannabinoidtype1receptorblockaderestoresneurologicalphenotypesintwomodelsfordownsyndrome AT jeanmichelrevest cannabinoidtype1receptorblockaderestoresneurologicalphenotypesintwomodelsfordownsyndrome AT piervincenzopiazza cannabinoidtype1receptorblockaderestoresneurologicalphenotypesintwomodelsfordownsyndrome AT fatimabosch cannabinoidtype1receptorblockaderestoresneurologicalphenotypesintwomodelsfordownsyndrome AT maradierssen cannabinoidtype1receptorblockaderestoresneurologicalphenotypesintwomodelsfordownsyndrome AT rafaeldelatorre cannabinoidtype1receptorblockaderestoresneurologicalphenotypesintwomodelsfordownsyndrome AT antoniorodriguezmoreno cannabinoidtype1receptorblockaderestoresneurologicalphenotypesintwomodelsfordownsyndrome AT rafaelmaldonado cannabinoidtype1receptorblockaderestoresneurologicalphenotypesintwomodelsfordownsyndrome AT andresozaita cannabinoidtype1receptorblockaderestoresneurologicalphenotypesintwomodelsfordownsyndrome |